Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 255 entries
Sorted by: Best Match Show Resources per page
WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.

Diagnostic microbiology and infectious disease

Jones RN, Sader HS, Fritsche TR, Janechek MJ.
PMID: 17919870
Diagn Microbiol Infect Dis. 2007 Oct 04; doi: 10.1016/j.diagmicrobio.2007.09.009. Epub 2007 Oct 04.

This article has been withdrawn consistent with Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). The Publisher apologizes for any inconvenience this may cause.

Cite
Jones RN, Sader HS, Fritsche TR, et al. WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagn Microbiol Infect Dis. 2007;doi: 10.1016/j.diagmicrobio.2007.09.009.
Jones, R. N., Sader, H. S., Fritsche, T. R., & Janechek, M. J. (2007). WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagnostic microbiology and infectious disease, . https://doi.org/10.1016/j.diagmicrobio.2007.09.009
Jones, Ronald N, et al. "WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem." Diagnostic microbiology and infectious disease vol. (2007). doi: https://doi.org/10.1016/j.diagmicrobio.2007.09.009
Jones RN, Sader HS, Fritsche TR, Janechek MJ. WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagn Microbiol Infect Dis. 2007 Oct 04; doi: 10.1016/j.diagmicrobio.2007.09.009. Epub 2007 Oct 04. PMID: 17919870.
Copy Download .nbib Format: NLM
Reply: regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians!.

Diagnostic microbiology and infectious disease

Jones RN, Mendes RE, Castanheira M.
PMID: 25064002
Diagn Microbiol Infect Dis. 2014 Jun 13; doi: 10.1016/j.diagmicrobio.2014.05.003. Epub 2014 Jun 13.

No abstract available.

Cite
Jones RN, Mendes RE, Castanheira M. Reply: regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians!. Diagn Microbiol Infect Dis. 2014;doi: 10.1016/j.diagmicrobio.2014.05.003.
Jones, R. N., Mendes, R. E., & Castanheira, M. (2014). Reply: regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians!. Diagnostic microbiology and infectious disease, . https://doi.org/10.1016/j.diagmicrobio.2014.05.003
Jones, Ronald N, et al. "Reply: regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians!." Diagnostic microbiology and infectious disease vol. (2014). doi: https://doi.org/10.1016/j.diagmicrobio.2014.05.003
Jones RN, Mendes RE, Castanheira M. Reply: regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians!. Diagn Microbiol Infect Dis. 2014 Jun 13; doi: 10.1016/j.diagmicrobio.2014.05.003. Epub 2014 Jun 13. PMID: 25064002.
Copy Download .nbib Format: NLM
Corrigendum to "Can procalcitonin differentiate Staphylococcus aureus from coagulase-negative staphylococci in clustered gram-positive bacteremia?" [Diagn Microbiol Infect Dis 2019;76(2):158-161].

Diagnostic microbiology and infectious disease

Shomali W, Hachem R, Chaftari AM, Bahu R, El Helou G, Jiang Y, Hanania AN, Reitzel R, Raad I.
PMID: 30852051
Diagn Microbiol Infect Dis. 2019 May;94(1):105. doi: 10.1016/j.diagmicrobio.2019.02.001. Epub 2019 Mar 06.

No abstract available.

Cite
Shomali W, Hachem R, Chaftari AM, et al. Corrigendum to "Can procalcitonin differentiate Staphylococcus aureus from coagulase-negative staphylococci in clustered gram-positive bacteremia?" [Diagn Microbiol Infect Dis 2019;76(2):158-161]. Diagn Microbiol Infect Dis. 2019;94(1):105doi: 10.1016/j.diagmicrobio.2019.02.001.
Shomali, W., Hachem, R., Chaftari, A. M., Bahu, R., El Helou, G., Jiang, Y., Hanania, A. N., Reitzel, R., & Raad, I. (2019). Corrigendum to "Can procalcitonin differentiate Staphylococcus aureus from coagulase-negative staphylococci in clustered gram-positive bacteremia?" [Diagn Microbiol Infect Dis 2019;76(2):158-161]. Diagnostic microbiology and infectious disease, 94(1), 105. https://doi.org/10.1016/j.diagmicrobio.2019.02.001
Shomali, William, et al. "Corrigendum to "Can procalcitonin differentiate Staphylococcus aureus from coagulase-negative staphylococci in clustered gram-positive bacteremia?" [Diagn Microbiol Infect Dis 2019;76(2):158-161]." Diagnostic microbiology and infectious disease vol. 94,1 (2019): 105. doi: https://doi.org/10.1016/j.diagmicrobio.2019.02.001
Shomali W, Hachem R, Chaftari AM, Bahu R, El Helou G, Jiang Y, Hanania AN, Reitzel R, Raad I. Corrigendum to "Can procalcitonin differentiate Staphylococcus aureus from coagulase-negative staphylococci in clustered gram-positive bacteremia?" [Diagn Microbiol Infect Dis 2019;76(2):158-161]. Diagn Microbiol Infect Dis. 2019 May;94(1):105. doi: 10.1016/j.diagmicrobio.2019.02.001. Epub 2019 Mar 06. PMID: 30852051.
Copy Download .nbib Format: NLM
Corrigendum to "Performance of Candida albicans germ tube antibodies (CAGTA) and its association with (1 → 3)-β-D-glucan (BDG) for diagnosis of invasive candidiasis (IC)" [Diagn Microbiol Infect Dis 2019;93(1):39-43].

Diagnostic microbiology and infectious disease

Pini P, Colombari B, Marchi E, Castagnoli A, Venturelli C, Sarti M, Blasi E.
PMID: 31027969
Diagn Microbiol Infect Dis. 2019 Jun;94(2):211. doi: 10.1016/j.diagmicrobio.2019.03.014. Epub 2019 Apr 23.

No abstract available.

Cite
Pini P, Colombari B, Marchi E, et al. Corrigendum to "Performance of Candida albicans germ tube antibodies (CAGTA) and its association with (1 → 3)-β-D-glucan (BDG) for diagnosis of invasive candidiasis (IC)" [Diagn Microbiol Infect Dis 2019;93(1):39-43]. Diagn Microbiol Infect Dis. 2019;94(2):211doi: 10.1016/j.diagmicrobio.2019.03.014.
Pini, P., Colombari, B., Marchi, E., Castagnoli, A., Venturelli, C., Sarti, M., & Blasi, E. (2019). Corrigendum to "Performance of Candida albicans germ tube antibodies (CAGTA) and its association with (1 → 3)-β-D-glucan (BDG) for diagnosis of invasive candidiasis (IC)" [Diagn Microbiol Infect Dis 2019;93(1):39-43]. Diagnostic microbiology and infectious disease, 94(2), 211. https://doi.org/10.1016/j.diagmicrobio.2019.03.014
Pini, Pietro, et al. "Corrigendum to "Performance of Candida albicans germ tube antibodies (CAGTA) and its association with (1 → 3)-β-D-glucan (BDG) for diagnosis of invasive candidiasis (IC)" [Diagn Microbiol Infect Dis 2019;93(1):39-43]." Diagnostic microbiology and infectious disease vol. 94,2 (2019): 211. doi: https://doi.org/10.1016/j.diagmicrobio.2019.03.014
Pini P, Colombari B, Marchi E, Castagnoli A, Venturelli C, Sarti M, Blasi E. Corrigendum to "Performance of Candida albicans germ tube antibodies (CAGTA) and its association with (1 → 3)-β-D-glucan (BDG) for diagnosis of invasive candidiasis (IC)" [Diagn Microbiol Infect Dis 2019;93(1):39-43]. Diagn Microbiol Infect Dis. 2019 Jun;94(2):211. doi: 10.1016/j.diagmicrobio.2019.03.014. Epub 2019 Apr 23. PMID: 31027969.
Copy Download .nbib Format: NLM
Evaluation of IS1245 LAMP in Mycobacterium avium and the influence of host-related genetic diversity on its application.

Diagnostic microbiology and infectious disease

Akapelwa ML, Kapalamula TF, Ouchi-Aizu Y, Hang'ombe BM, Nishiuchi Y, Gordon SV, Solo ES, Tamaru A, Nishimura T, Hasegawa N, Morimoto K, Fukushima Y, Suzuki Y, Nakajima C.
PMID: 34391980
Diagn Microbiol Infect Dis. 2021 Dec;101(4):115494. doi: 10.1016/j.diagmicrobio.2021.115494. Epub 2021 Jul 21.

Early detection and treatment are paramount for the timely control of Mycobacterium avium infections. Herein, we designed a LAMP assay targeting a widely used species-specific marker IS1245 for the rapid detection of M. avium and evaluated its applicability using...

Cite
Akapelwa ML, Kapalamula TF, Ouchi-Aizu Y, et al. Evaluation of IS1245 LAMP in Mycobacterium avium and the influence of host-related genetic diversity on its application. Diagn Microbiol Infect Dis. 2021;101(4):115494doi: 10.1016/j.diagmicrobio.2021.115494.
Akapelwa, M. L., Kapalamula, T. F., Ouchi-Aizu, Y., Hang'ombe, B. M., Nishiuchi, Y., Gordon, S. V., Solo, E. S., Tamaru, A., Nishimura, T., Hasegawa, N., Morimoto, K., Fukushima, Y., Suzuki, Y., & Nakajima, C. (2021). Evaluation of IS1245 LAMP in Mycobacterium avium and the influence of host-related genetic diversity on its application. Diagnostic microbiology and infectious disease, 101(4), 115494. https://doi.org/10.1016/j.diagmicrobio.2021.115494
Akapelwa, Mwangala Lonah, et al. "Evaluation of IS1245 LAMP in Mycobacterium avium and the influence of host-related genetic diversity on its application." Diagnostic microbiology and infectious disease vol. 101,4 (2021): 115494. doi: https://doi.org/10.1016/j.diagmicrobio.2021.115494
Akapelwa ML, Kapalamula TF, Ouchi-Aizu Y, Hang'ombe BM, Nishiuchi Y, Gordon SV, Solo ES, Tamaru A, Nishimura T, Hasegawa N, Morimoto K, Fukushima Y, Suzuki Y, Nakajima C. Evaluation of IS1245 LAMP in Mycobacterium avium and the influence of host-related genetic diversity on its application. Diagn Microbiol Infect Dis. 2021 Dec;101(4):115494. doi: 10.1016/j.diagmicrobio.2021.115494. Epub 2021 Jul 21. PMID: 34391980.
Copy Download .nbib Format: NLM
OXA-181 carbapenemase carried on an IncX3 plasmid in high-risk Escherichia coli ST167 isolated from a traveler returning from Sub-Saharan Africa to Brazil.

Diagnostic microbiology and infectious disease

Santos Tufic-Garutti SD, de Araújo Longo LG, Fontana H, Garutti LHG, de Carvalho Girão VB, Fuga B, Lincopan N, de Pinho Rodrigues KM, Moreira BM.
PMID: 34739936
Diagn Microbiol Infect Dis. 2022 Jan;102(1):115570. doi: 10.1016/j.diagmicrobio.2021.115570. Epub 2021 Oct 08.

This is the first detection and genomic analysis of an OXA-181-carbapenemase-producing E. coli in Brazil, from a traveler returning from Sub-Saharan Africa. The ST167 isolate carries bla

Cite
Santos Tufic-Garutti SD, de Araújo Longo LG, Fontana H, et al. OXA-181 carbapenemase carried on an IncX3 plasmid in high-risk Escherichia coli ST167 isolated from a traveler returning from Sub-Saharan Africa to Brazil. Diagn Microbiol Infect Dis. 2021;102(1):115570doi: 10.1016/j.diagmicrobio.2021.115570.
Santos Tufic-Garutti, S. D., de Araújo Longo, L. G., Fontana, H., Garutti, L. H. G., de Carvalho Girão, V. B., Fuga, B., Lincopan, N., de Pinho Rodrigues, K. M., & Moreira, B. M. (2022). OXA-181 carbapenemase carried on an IncX3 plasmid in high-risk Escherichia coli ST167 isolated from a traveler returning from Sub-Saharan Africa to Brazil. Diagnostic microbiology and infectious disease, 102(1), 115570. https://doi.org/10.1016/j.diagmicrobio.2021.115570
Santos Tufic-Garutti, Samantha Dos, et al. "OXA-181 carbapenemase carried on an IncX3 plasmid in high-risk Escherichia coli ST167 isolated from a traveler returning from Sub-Saharan Africa to Brazil." Diagnostic microbiology and infectious disease vol. 102,1 (2022): 115570. doi: https://doi.org/10.1016/j.diagmicrobio.2021.115570
Santos Tufic-Garutti SD, de Araújo Longo LG, Fontana H, Garutti LHG, de Carvalho Girão VB, Fuga B, Lincopan N, de Pinho Rodrigues KM, Moreira BM. OXA-181 carbapenemase carried on an IncX3 plasmid in high-risk Escherichia coli ST167 isolated from a traveler returning from Sub-Saharan Africa to Brazil. Diagn Microbiol Infect Dis. 2022 Jan;102(1):115570. doi: 10.1016/j.diagmicrobio.2021.115570. Epub 2021 Oct 08. PMID: 34739936.
Copy Download .nbib Format: NLM
The potential of volatile organic compounds-based breath analysis for COVID-19 screening: a systematic review & meta-analysis.

Diagnostic microbiology and infectious disease

Subali AD, Wiyono L, Yusuf M, Zaky MFA.
PMID: 34879323
Diagn Microbiol Infect Dis. 2021 Oct 30;102(2):115589. doi: 10.1016/j.diagmicrobio.2021.115589. Epub 2021 Oct 30.

COVID-19 is a major problem with an increasing incidence and mortality. The discovery of Volatile Organic Compounds (VOCs) based on breath analysis offers a reliable, rapid, and affordable screening method. This study examined VOC-based breath analysis diagnostic performance for...

Cite
Subali AD, Wiyono L, Yusuf M, et al. The potential of volatile organic compounds-based breath analysis for COVID-19 screening: a systematic review & meta-analysis. Diagn Microbiol Infect Dis. 2021;102(2):115589doi: 10.1016/j.diagmicrobio.2021.115589.
Subali, A. D., Wiyono, L., Yusuf, M., & Zaky, M. F. A. (2021). The potential of volatile organic compounds-based breath analysis for COVID-19 screening: a systematic review & meta-analysis. Diagnostic microbiology and infectious disease, 102(2), 115589. https://doi.org/10.1016/j.diagmicrobio.2021.115589
Subali, Anita Dominique, et al. "The potential of volatile organic compounds-based breath analysis for COVID-19 screening: a systematic review & meta-analysis." Diagnostic microbiology and infectious disease vol. 102,2 (2021): 115589. doi: https://doi.org/10.1016/j.diagmicrobio.2021.115589
Subali AD, Wiyono L, Yusuf M, Zaky MFA. The potential of volatile organic compounds-based breath analysis for COVID-19 screening: a systematic review & meta-analysis. Diagn Microbiol Infect Dis. 2021 Oct 30;102(2):115589. doi: 10.1016/j.diagmicrobio.2021.115589. Epub 2021 Oct 30. PMID: 34879323; PMCID: PMC8556067.
Copy Download .nbib Format: NLM
Clinical outcomes of combination versus monotherapy for gram negative non-HACEK infective endocarditis.

Diagnostic microbiology and infectious disease

Lorenz A, Sobhanie MME, Orzel L, Coe K, Wardlow L.
PMID: 34375862
Diagn Microbiol Infect Dis. 2021 Nov;101(3):115504. doi: 10.1016/j.diagmicrobio.2021.115504. Epub 2021 Jul 24.

The objective of this single-center, retrospective cohort study was to identify whether combination therapy is associated with a lower rate of adverse outcomes for the treatment of Gram negative non-HACEK IE. The primary endpoint was a composite of 60-day...

Cite
Lorenz A, Sobhanie MME, Orzel L, et al. Clinical outcomes of combination versus monotherapy for gram negative non-HACEK infective endocarditis. Diagn Microbiol Infect Dis. 2021;101(3):115504doi: 10.1016/j.diagmicrobio.2021.115504.
Lorenz, A., Sobhanie, M. M. E., Orzel, L., Coe, K., & Wardlow, L. (2021). Clinical outcomes of combination versus monotherapy for gram negative non-HACEK infective endocarditis. Diagnostic microbiology and infectious disease, 101(3), 115504. https://doi.org/10.1016/j.diagmicrobio.2021.115504
Lorenz, Ashley, et al. "Clinical outcomes of combination versus monotherapy for gram negative non-HACEK infective endocarditis." Diagnostic microbiology and infectious disease vol. 101,3 (2021): 115504. doi: https://doi.org/10.1016/j.diagmicrobio.2021.115504
Lorenz A, Sobhanie MME, Orzel L, Coe K, Wardlow L. Clinical outcomes of combination versus monotherapy for gram negative non-HACEK infective endocarditis. Diagn Microbiol Infect Dis. 2021 Nov;101(3):115504. doi: 10.1016/j.diagmicrobio.2021.115504. Epub 2021 Jul 24. PMID: 34375862; PMCID: PMC8574162.
Copy Download .nbib Format: NLM
Phenotypic drug susceptibility testing of rapid growing mycobacteria and the issue of antibiotic stability.

Diagnostic microbiology and infectious disease

Wetzstein N, Wichelhaus TA.
PMID: 34678713
Diagn Microbiol Infect Dis. 2022 Jan;102(1):115555. doi: 10.1016/j.diagmicrobio.2021.115555. Epub 2021 Sep 24.

Phenotypic drug susceptibility testing is a valuable tool to guide therapy in rapid growing mycobacteria. Beta lactams, however, exhibit insufficient stability during a 5-day incubation period in minimal inhibitory concentration (MIC) testing as well as in time kill kinetics...

Cite
Wetzstein N, Wichelhaus TA. Phenotypic drug susceptibility testing of rapid growing mycobacteria and the issue of antibiotic stability. Diagn Microbiol Infect Dis. 2021;102(1):115555doi: 10.1016/j.diagmicrobio.2021.115555.
Wetzstein, N., & Wichelhaus, T. A. (2022). Phenotypic drug susceptibility testing of rapid growing mycobacteria and the issue of antibiotic stability. Diagnostic microbiology and infectious disease, 102(1), 115555. https://doi.org/10.1016/j.diagmicrobio.2021.115555
Wetzstein, Nils, and Wichelhaus, Thomas A. "Phenotypic drug susceptibility testing of rapid growing mycobacteria and the issue of antibiotic stability." Diagnostic microbiology and infectious disease vol. 102,1 (2022): 115555. doi: https://doi.org/10.1016/j.diagmicrobio.2021.115555
Wetzstein N, Wichelhaus TA. Phenotypic drug susceptibility testing of rapid growing mycobacteria and the issue of antibiotic stability. Diagn Microbiol Infect Dis. 2022 Jan;102(1):115555. doi: 10.1016/j.diagmicrobio.2021.115555. Epub 2021 Sep 24. PMID: 34678713.
Copy Download .nbib Format: NLM
Evaluation of the selection of cerebrospinal fluid testing in suspected meningitis and encephalitis.

Diagnostic microbiology and infectious disease

Morrison AR, Jones MC, Makowski CT, Samuel LP, Ramadan AR, Alangaden GJ, Davis SL, Kenney RM.
PMID: 34768207
Diagn Microbiol Infect Dis. 2022 Jan;102(1):115571. doi: 10.1016/j.diagmicrobio.2021.115571. Epub 2021 Oct 11.

Diagnostic stewardship interventions can decrease unnecessary antimicrobial therapy and microbiology laboratory resources and costs. This retrospective cross-sectional study evaluated factors associated with inappropriate initial cerebrospinal fluid (CSF) testing in patients with suspected community-acquired meningitis or encephalitis. In 250 patients,...

Cite
Morrison AR, Jones MC, Makowski CT, et al. Evaluation of the selection of cerebrospinal fluid testing in suspected meningitis and encephalitis. Diagn Microbiol Infect Dis. 2021;102(1):115571doi: 10.1016/j.diagmicrobio.2021.115571.
Morrison, A. R., Jones, M. C., Makowski, C. T., Samuel, L. P., Ramadan, A. R., Alangaden, G. J., Davis, S. L., & Kenney, R. M. (2022). Evaluation of the selection of cerebrospinal fluid testing in suspected meningitis and encephalitis. Diagnostic microbiology and infectious disease, 102(1), 115571. https://doi.org/10.1016/j.diagmicrobio.2021.115571
Morrison, Austin R, et al. "Evaluation of the selection of cerebrospinal fluid testing in suspected meningitis and encephalitis." Diagnostic microbiology and infectious disease vol. 102,1 (2022): 115571. doi: https://doi.org/10.1016/j.diagmicrobio.2021.115571
Morrison AR, Jones MC, Makowski CT, Samuel LP, Ramadan AR, Alangaden GJ, Davis SL, Kenney RM. Evaluation of the selection of cerebrospinal fluid testing in suspected meningitis and encephalitis. Diagn Microbiol Infect Dis. 2022 Jan;102(1):115571. doi: 10.1016/j.diagmicrobio.2021.115571. Epub 2021 Oct 11. PMID: 34768207.
Copy Download .nbib Format: NLM
Genetic determinants of virulence and antibiotic resistance are common for Pseudomonas aeruginosa ST235 isolates from cystic fibrosis patients from various geographical regions.

Diagnostic microbiology and infectious disease

Savinova T, Bocharova Y, Mayanskiy N, Chebotar I.
PMID: 34902620
Diagn Microbiol Infect Dis. 2021 Nov 18;102(3):115596. doi: 10.1016/j.diagmicrobio.2021.115596. Epub 2021 Nov 18.

The dissemination of multiple-drug resistant high virulent strains of P. aeruginosa in patients with cystic fibrosis is of concern worldwide. Herein, we describe genomic characteristics of ST235 isolates recovered from cystic fibrosis patients in Russia. Successful core-genome background and...

Cite
Savinova T, Bocharova Y, Mayanskiy N, et al. Genetic determinants of virulence and antibiotic resistance are common for Pseudomonas aeruginosa ST235 isolates from cystic fibrosis patients from various geographical regions. Diagn Microbiol Infect Dis. 2021;102(3):115596doi: 10.1016/j.diagmicrobio.2021.115596.
Savinova, T., Bocharova, Y., Mayanskiy, N., & Chebotar, I. (2021). Genetic determinants of virulence and antibiotic resistance are common for Pseudomonas aeruginosa ST235 isolates from cystic fibrosis patients from various geographical regions. Diagnostic microbiology and infectious disease, 102(3), 115596. https://doi.org/10.1016/j.diagmicrobio.2021.115596
Savinova, Tatiana, et al. "Genetic determinants of virulence and antibiotic resistance are common for Pseudomonas aeruginosa ST235 isolates from cystic fibrosis patients from various geographical regions." Diagnostic microbiology and infectious disease vol. 102,3 (2021): 115596. doi: https://doi.org/10.1016/j.diagmicrobio.2021.115596
Savinova T, Bocharova Y, Mayanskiy N, Chebotar I. Genetic determinants of virulence and antibiotic resistance are common for Pseudomonas aeruginosa ST235 isolates from cystic fibrosis patients from various geographical regions. Diagn Microbiol Infect Dis. 2021 Nov 18;102(3):115596. doi: 10.1016/j.diagmicrobio.2021.115596. Epub 2021 Nov 18. PMID: 34902620.
Copy Download .nbib Format: NLM
Incidence and utility of follow-up blood cultures in cancer patients with gram-negative bacteremia.

Diagnostic microbiology and infectious disease

Clemmons AB, Young HN, Bland CM, Jackson B, Hayashi M, Folsom C, Chastain DB.
PMID: 34186321
Diagn Microbiol Infect Dis. 2021 Oct;101(2):115444. doi: 10.1016/j.diagmicrobio.2021.115444. Epub 2021 May 29.

Benefit of follow-up blood cultures (FUBC) in cancer patients with gram-negative bacteremia (GNB) is unknown. Multicenter, retrospective review was performed in adult cancer patients with GNB between January and December 2018. Primary outcome was FUBC incidence. Chi-square, t-tests/Wilcoxon rank-sum,...

Cite
Clemmons AB, Young HN, Bland CM, et al. Incidence and utility of follow-up blood cultures in cancer patients with gram-negative bacteremia. Diagn Microbiol Infect Dis. 2021;101(2):115444doi: 10.1016/j.diagmicrobio.2021.115444.
Clemmons, A. B., Young, H. N., Bland, C. M., Jackson, B., Hayashi, M., Folsom, C., & Chastain, D. B. (2021). Incidence and utility of follow-up blood cultures in cancer patients with gram-negative bacteremia. Diagnostic microbiology and infectious disease, 101(2), 115444. https://doi.org/10.1016/j.diagmicrobio.2021.115444
Clemmons, Amber B, et al. "Incidence and utility of follow-up blood cultures in cancer patients with gram-negative bacteremia." Diagnostic microbiology and infectious disease vol. 101,2 (2021): 115444. doi: https://doi.org/10.1016/j.diagmicrobio.2021.115444
Clemmons AB, Young HN, Bland CM, Jackson B, Hayashi M, Folsom C, Chastain DB. Incidence and utility of follow-up blood cultures in cancer patients with gram-negative bacteremia. Diagn Microbiol Infect Dis. 2021 Oct;101(2):115444. doi: 10.1016/j.diagmicrobio.2021.115444. Epub 2021 May 29. PMID: 34186321.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 255 entries